439 related articles for article (PubMed ID: 24893886)
1. The normal and pathologic roles of the Alzheimer's β-secretase, BACE1.
Kandalepas PC; Vassar R
Curr Alzheimer Res; 2014; 11(5):441-9. PubMed ID: 24893886
[TBL] [Abstract][Full Text] [Related]
2. BACE1 elevation is involved in amyloid plaque development in the triple transgenic model of Alzheimer's disease: differential Aβ antibody labeling of early-onset axon terminal pathology.
Cai Y; Zhang XM; Macklin LN; Cai H; Luo XG; Oddo S; Laferla FM; Struble RG; Rose GM; Patrylo PR; Yan XX
Neurotox Res; 2012 Feb; 21(2):160-74. PubMed ID: 21725719
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes.
Ly PT; Wu Y; Zou H; Wang R; Zhou W; Kinoshita A; Zhang M; Yang Y; Cai F; Woodgett J; Song W
J Clin Invest; 2013 Jan; 123(1):224-35. PubMed ID: 23202730
[TBL] [Abstract][Full Text] [Related]
4. BACE1 in Alzheimer's disease.
Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
[TBL] [Abstract][Full Text] [Related]
5. BACE1: the beta-secretase enzyme in Alzheimer's disease.
Vassar R
J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
[TBL] [Abstract][Full Text] [Related]
6. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
Vassar R
J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
[TBL] [Abstract][Full Text] [Related]
7. BACE1 structure and function in health and Alzheimer's disease.
Cole SL; Vassar R
Curr Alzheimer Res; 2008 Apr; 5(2):100-20. PubMed ID: 18393796
[TBL] [Abstract][Full Text] [Related]
8. Beta-secretase-1 elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development.
Zhang XM; Cai Y; Xiong K; Cai H; Luo XG; Feng JC; Clough RW; Struble RG; Patrylo PR; Yan XX
Eur J Neurosci; 2009 Dec; 30(12):2271-83. PubMed ID: 20092570
[TBL] [Abstract][Full Text] [Related]
9. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
[TBL] [Abstract][Full Text] [Related]
10. BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease.
Barão S; Moechars D; Lichtenthaler SF; De Strooper B
Trends Neurosci; 2016 Mar; 39(3):158-169. PubMed ID: 26833257
[TBL] [Abstract][Full Text] [Related]
11. Tau deletion reduces plaque-associated BACE1 accumulation and decelerates plaque formation in a mouse model of Alzheimer's disease.
Peters F; Salihoglu H; Pratsch K; Herzog E; Pigoni M; Sgobio C; Lichtenthaler SF; Neumann U; Herms J
EMBO J; 2019 Dec; 38(23):e102345. PubMed ID: 31701556
[TBL] [Abstract][Full Text] [Related]
12. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer's disease.
Sadleir KR; Kandalepas PC; Buggia-Prévot V; Nicholson DA; Thinakaran G; Vassar R
Acta Neuropathol; 2016 Aug; 132(2):235-256. PubMed ID: 26993139
[TBL] [Abstract][Full Text] [Related]
13. Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis.
Zhao J; Fu Y; Yasvoina M; Shao P; Hitt B; O'Connor T; Logan S; Maus E; Citron M; Berry R; Binder L; Vassar R
J Neurosci; 2007 Apr; 27(14):3639-49. PubMed ID: 17409228
[TBL] [Abstract][Full Text] [Related]
14. The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential.
Vassar R; Kovacs DM; Yan R; Wong PC
J Neurosci; 2009 Oct; 29(41):12787-94. PubMed ID: 19828790
[TBL] [Abstract][Full Text] [Related]
15. Aberrant proteolytic processing and therapeutic strategies in Alzheimer disease.
Tomita T
Adv Biol Regul; 2017 May; 64():33-38. PubMed ID: 28082052
[TBL] [Abstract][Full Text] [Related]
16. The Alzheimer's β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques.
Kandalepas PC; Sadleir KR; Eimer WA; Zhao J; Nicholson DA; Vassar R
Acta Neuropathol; 2013 Sep; 126(3):329-52. PubMed ID: 23820808
[TBL] [Abstract][Full Text] [Related]
17. Beta-secretase (BACE) as a drug target for Alzheimer's disease.
Vassar R
Adv Drug Deliv Rev; 2002 Dec; 54(12):1589-602. PubMed ID: 12453676
[TBL] [Abstract][Full Text] [Related]
18. Aβ reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level.
Sadleir KR; Eimer WA; Cole SL; Vassar R
Mol Neurodegener; 2015 Jan; 10():1. PubMed ID: 25567526
[TBL] [Abstract][Full Text] [Related]
19. Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic.
Hook G; Yu J; Toneff T; Kindy M; Hook V
J Alzheimers Dis; 2014; 41(1):129-49. PubMed ID: 24595198
[TBL] [Abstract][Full Text] [Related]
20. BACE1 as a therapeutic target in Alzheimer's disease: rationale and current status.
Evin G; Hince C
Drugs Aging; 2013 Oct; 30(10):755-64. PubMed ID: 23842796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
